- Home
- ILLR vs ANNX Comparison
ILLR vs ANNX Comparison
Compare ILLR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ANNX
- Stock Information
- Founded
- ILLR 2015
- ANNX 2011
- Country
- ILLR United States
- ANNX United States
- Employees
- ILLR N/A
- ANNX N/A
- Industry
- ILLR Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ANNX Health Care
- Exchange
- ILLR Nasdaq
- ANNX Nasdaq
- Market Cap
- ILLR 304.1M
- ANNX 362.4M
- IPO Year
- ILLR N/A
- ANNX 2020
- Fundamental
- Price
- ILLR $0.61
- ANNX $2.25
- Analyst Decision
- ILLR
- ANNX Strong Buy
- Analyst Count
- ILLR 0
- ANNX 7
- Target Price
- ILLR N/A
- ANNX $15.80
- AVG Volume (30 Days)
- ILLR 436.9K
- ANNX 1.6M
- Earning Date
- ILLR 05-15-2025
- ANNX 03-03-2025
- Dividend Yield
- ILLR N/A
- ANNX N/A
- EPS Growth
- ILLR N/A
- ANNX N/A
- EPS
- ILLR N/A
- ANNX N/A
- Revenue
- ILLR $45,244,000.00
- ANNX N/A
- Revenue This Year
- ILLR N/A
- ANNX N/A
- Revenue Next Year
- ILLR N/A
- ANNX N/A
- P/E Ratio
- ILLR N/A
- ANNX N/A
- Revenue Growth
- ILLR N/A
- ANNX N/A
- 52 Week Low
- ILLR $0.53
- ANNX $2.18
- 52 Week High
- ILLR $8.86
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- ANNX 36.33
- Support Level
- ILLR N/A
- ANNX $2.18
- Resistance Level
- ILLR N/A
- ANNX $2.75
- Average True Range (ATR)
- ILLR 0.00
- ANNX 0.25
- MACD
- ILLR 0.00
- ANNX 0.01
- Stochastic Oscillator
- ILLR 0.00
- ANNX 5.26
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.